Skandinaviska Enskilda Banken AB publ Increases Stake in Humana Inc. (NYSE:HUM)

Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Humana Inc. (NYSE:HUM) by 0.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,097 shares of the insurance provider’s stock after purchasing an additional 84 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Humana were worth $6,127,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Achmea Investment Management B.V. grew its stake in Humana by 6.7% during the fourth quarter. Achmea Investment Management B.V. now owns 10,330 shares of the insurance provider’s stock valued at $2,621,000 after acquiring an additional 651 shares in the last quarter. Vestcor Inc grew its position in shares of Humana by 146.3% during the 4th quarter. Vestcor Inc now owns 5,914 shares of the insurance provider’s stock valued at $1,500,000 after purchasing an additional 3,513 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Humana by 4.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,103 shares of the insurance provider’s stock worth $533,000 after purchasing an additional 81 shares during the period. Wealthfront Advisers LLC raised its position in shares of Humana by 130.7% in the fourth quarter. Wealthfront Advisers LLC now owns 31,408 shares of the insurance provider’s stock worth $7,969,000 after buying an additional 17,793 shares in the last quarter. Finally, River Road Asset Management LLC bought a new stake in Humana during the fourth quarter valued at $3,465,000. Institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.32% of the stock is owned by corporate insiders.

Humana Trading Up 0.5 %

NYSE HUM opened at $253.11 on Friday. The stock’s 50 day moving average is $271.37 and its 200 day moving average is $280.01. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $30.55 billion, a PE ratio of 25.44, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana’s payout ratio is currently 35.58%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Truist Financial raised their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.